The combined use of active ingredients allows the treatment of difficult-to-treat forms – healing practice

Improved treatment of triple negative breast cancer

A combination of drugs already approved for other types of cancer appears to be an effective treatment forms of breast cancer that are particularly difficult to treat to allow.

In a new study involving experts from Louisiana State University they were using a mouse pattern and the fabric of women with triple negative breast cancer (triple negative breast cancer) looked at a total of 133 drugs already approved by the FDA in the US, including the drugs ceritinib and enzalutamide.

The results were published in the English-language journal “Molecular Cancer”.

Triple negative breast cancer risk

Triple negative breast cancer often affects younger women. Women of African and Hispanic descent and women with deleterious germline mutations in breast cancer susceptibility genes are also more likely to develop this form of cancer, the researchers explain.

This aggressive type of breast cancer 15 to 20 percent of all breast cancers out.

What is ceritinib?

Drug Ceritinib According to the team, it is a so-called low molecular weight tyrosine kinase inhibitor. Ceritinib is usually used to treat people with non-small cell lung cancer Used.

What is Enzalutamide?

to Enzalutamide On the other hand, it is a low molecular weight drug that targets the androgen receptor as well prostate cancer treatment is being used, the researchers explain.

Combined treatment of triple negative breast cancer

Want both drugs combinedthis seems effective for treatment chemoresistant triple negative breast cancer to be. This form of cancer lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2).

Androgen receptors as the target of cancer treatment

A subtype of this cancer, that 12 to 55 percent of triple-negative breast cancers constitutes, has androgen receptors (AR). Because androgen receptors stimulate the progression of cancer cells in estrogen receptor-negative breast cancer, they represent a target in therapy for triple-negative breast cancer, the team said.

Many affected women are resistant to paclitaxel

A Problem in the treatment of triple negative breast cancer is, according to experts, that a significant number of sick women have a Resistance to paclitaxel developed.

Paclitaxel is a drug approved by the FDA as a chemotherapy drug for triple negative breast cancer. Therefore, new therapeutic approaches are needed. The FDA is the US Food and Drug Administration.

What did the combined treatment achieve?

Eventually, the researchers found in their study that Ceritinib effectively inhibits the growth of triple negative androgen receptor breast cancer cells. To improve the response to the drug, they also chose enzalutamide, an androgen receptor antagonist.

We have developed a new enzalutamide and ceritinib combination strategy for the treatment of AR + TNBC tumors through double blocking of androgen-dependent and androgen-independent AR signaling‘explains the author of the study Dr. Sure Alahari in a press release.

Inhibited growth of AR + TNBC cells

It was found that a combination of ceritinib and enzalutamide strong inhibitory effect on AR + TNBC cell growth carries with it. A combination of paclitaxel and ceritinib was also studied, which was shown to have beneficial effects.

The combination of paclitaxel and ceritinib showed dramatic inhibition of tumor growth compared to both agents alone. All agents used in our study are FDA approved, so the proposed combination therapy is likely to be used in the clinic as well“, he adds Dr. Alahari added. (how)

Information on the author and source

This text corresponds to the specifications of the specialist medical literature, medical guidelines and current studies and has been verified by medical professionals.


  • Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, et al .: Ceritinib is a new therapeutic agent for triple negative breast cancer; in: Molecular cancer (veröffentlicht 29.06.2022), Molecular cancer
  • Louisiana State University Health Sciences Center: LSU Health Research suggests new combination therapy for triple negative breast cancer (veröffentlicht 29.06.2022), Louisiana State University Health Sciences Center

Important note:
This article contains general advice only and is not to be used for self-diagnosis or treatment. It cannot replace a visit to the doctor.

Leave a Comment